Clinical characteristics of neuro-Behcet’s disease in Japan: a multicenter retrospective analysis

References

• Hirohata S, Kikuchi H. Behçet's disease. Arthritis Res Ther. 2003;5:139–46.
   PubMed Web of Science ®Google Scholar
• Serdaroglu P. Behçet's disease and the nervous system. J Neurol. 1998;245:197–205.
   PubMed Web of Science ®Google Scholar
• Kidd D, Steuer A, Denman AM, Rudge P. Neurological com-plications in Behçet's syndrome. Brain. 1999;122:2183–94.
   PubMed Web of Science ®Google Scholar
• Siva A, Altintas A, Saip S. Behçet's syndrome and the nervous system. Curr Opin Neurol. 2004;17:347–57.
   PubMed Web of Science ®Google Scholar
• Akman-Demir G, Serdaroglu P, Tasci B. The Neuro-Behçet Study Group. Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. Brain. 1999;122: 2171–82.
   Google Scholar
• Hirohata S, Isshi K, Oguchi H, Ohse T, Haraoka H, Takeuchi A, et al. Cerebrospinal fluid interleukin-6 in progressive Neuro-Behcet's syndrome. Clin Immunol Immunopathol. 1997;82:12–7.
   PubMedGoogle Scholar
• Hirohata S. Potential new therapeutic options for involvement of central nervous system in Behçet's disease (Neuro-Behget's syndrome). Curr Rheumatol Rev. 2007;3:297–303.
   Google Scholar
• Siva A, Hirohata S. Behçet's syndrome and the nervous system. In: Yazici Y, Yazici H, editors. Behçet's syndrome. New York: Springer; 2010. p. 95–113.
   Google Scholar
• International Study Group for Behcet's disease. Criteria for diagnosis of Behcet's disease. Lancet. 1990;335:1078–80.
   PubMed Web of Science ®Google Scholar
• Aramaki K, Kikuchi H, Hirohata S. HLA-B51 and cigarette smoking as risk factors for chronic progressive neurological man-ifestations in Behcet's disease. Mod Rheumatol. 2007;17: 81–2.
   Google Scholar
• Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H. Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. Ophthalmology. 1999;106:586–9.
   PubMed Web of Science ®Google Scholar
• Dzudie A, Boissonnat P, Roussoulieres A, Cakmak, Mosbah K, Bejui Fr, Obadia JF, Sebbag L. Cyclosporine-related posterior reversible encephalopathy syndrome after heart transplantation: should we withdraw or reduce cyclosporine?: case reports. Transplant Proc. 2009;41:716–20.
   PubMed Web of Science ®Google Scholar
• Akman-Demir G, Ayranci 0, Kurtuncu M, Vanli EN, Mutlu M, Tugal-Tutkun I. Cyclosporine for Behçet's uveitis: is it associated with an increased risk of neurological involvement? Clin Exp Rheumatol. 2008;26(Suppl 50):584–90.
   Google Scholar
• Hirohata S, Suda H, Hashimoto T. Low-dose weekly metho-trexate for progressive neuropsychiatric manifestations in Behçet's disease. J Neurol Sci. 1998;159:181–5.
   Google Scholar
• Saip S, Siva A, Altintas A, Kiyat A, Seyahi E, Hamuryudan V, et al. Headache in Behçet's syndrome. Headache. 2005;45:911–9.
   PubMed Web of Science ®Google Scholar
• Koger N, Islak C, Siva A, Saip S, Akman C, Kantarci 0, et al. CNS involvement in neuro-Behçet's syndrome: an MR study. Am J Neuroradiol. 1999;20: 1015–24.
   Google Scholar
• Al-Araji A, Kidd DP. Neuro-Behçet's disease: epidemiology, clinical characteristics, and management. Lancet Neurol. 2009;8: 192–204.
   Google Scholar
• Hirohata S, Takeuchi A, Miyamoto T. Elevated levels of inter-leukin 6 in cerebrospinal fluid from patients with Neuro-Behçet's syndrome. In: O'Duffy JD, Kokmen E, editors. Behçet's disease. New York: Marcel Dekker; 1991. p. 369–76.
   Google Scholar
• Fujikawa K, Aratake K, Kawakami A, Aramaki T, Iwanaga N, Izumi Y, et al. Successful treatment of refractory neuro-Behcet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile. Ann Rheum Dis. 2007;66:136–7.
   PubMed Web of Science ®Google Scholar
• Akman-Demir G, 'Raft E, köz S, YeOlot N, Yentfir SP, aw-l-Una' M, et al. Interleukin-6 in neuro-Behçet's disease: associa-tion with disease subsets and long-term outcome. Cytokine. 2008;44: 373–6.
   Google Scholar
• Haghighi AB, Ittehadi H, Nikseresht AR, Rahmati J, Poorjahromi SG, Pourabbas B, et al. CSF levels of cytokines in neuro-Behçet's disease. Clin Neurol Neurosurg. 2009;111:507–10.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Doolittle TH, Lincoln R, Brown RH, Dinarello CA. Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology. 1990;40: 1735–9.
   Google Scholar
• Ishizu T, Osoegawa M, Mei FJ, Kikuchi H, Tanaka M, Takakura Y, Minohara M, Murai H, Mihara F, Taniwaki T, Kira J. Intra-thecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain. 2005;128: 988–1002.
   Google Scholar